



Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507

Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com

January 26, 2023

To,
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Copies of newspaper advertisement regarding unaudited financial results for the quarter and nine months ended December 31, 2022

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, please find enclosed copies of newspaper advertisement regarding the unaudited financial results of the company for the quarter and nine months ended December 31, 2022, as published in Business Standard and Andhra Prabha on January 26, 2023.

This is for your information and records

Thanking you.

Yours faithfully,
For Dr. Reddy's Laboratories Limited

K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR

Encl: as above

1 The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the NSE Limited (www.nseindia.com), BSE Limited (www.bseindia.com) and at the Company's website (www.solara.co.in)

2 The above consolidated financial results of Solara Active Pharma Sciences Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on January 25, 2023. The results for the quarter ended and nine months ended December 31, 2022 has been reviewed by Deloitte Haskins & Sells LLP, the statutory auditors of the Company. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter ended and nine months ended December 31, 2022.

For and on behalf of board
Sd/-

Place : Bengaluru
Date : January 25, 2023

Jitesh Devendra
Managing Director

Business Standard on January 26, 2023



Sr. No.	
1	Total Income
2	Net profit for
3	Net profit for
4	Net profit for
5	Total compr (after tax) al
6	Paid up equ
7	Reserves (e
8	Securities p
9	Net worth
10	Paid up deb
11	Outstanding
12	Debt equity
13	Earnings per
	1. Basic
	2. Diluted
14	Capital rede
15	Debenture f
16	Debt service
17	Interest sen

Notes:
1. The above resu
Board of Directors
2. The above is an
52 of the Securitie
the quarterly finan
at www.phoenixar
Disclosure Requir
accessed on the v
3. The company is
business of the co
AS 108 "Operatin
4. COVID-19 a glo
2023 due to an im
demic will impact
5. Figures for the

Place: Mumbai
Date: January 2

Dr.Reddy's

Extract of unaudited financial results of Dr. Reddy's Laboratories Limited and its subsidiaries for the quarter and nine months ended 31 December 2022 prepared in compliance with Indian Accounting Standards

All amounts in Indian Rupees millions

Sl. No.	Particulars	Consolidated					
		Quarter ended	Quarter ended	Quarter ended	Nine Months ended	Nine Months ended	Year ended
		31.12.2022 (Unaudited)	30.09.2022 (Unaudited)	31.12.2021 (Unaudited)	31.12.2022 (Unaudited)	31.12.2021 (Unaudited)	31.03.2022 (Audited)
1	Total Revenue from operations	67,898	63,318	53,383	183,545	160,703	215,452
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	16,377	16,136	9,742	47,193	28,025	30,614
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	16,377	16,136	9,742	47,193	28,025	30,614
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	12,439	11,142	7,093	35,471	20,855	21,825
5	Total Comprehensive Income for the period	14,143	10,521	5,855	34,425	18,457	18,927
6	Equity Share Capital	833	832	832	833	832	832
7	Reserves (excluding Revaluation Reserve)						191,292
8	Earnings per share (in Rupees) per Rs. 5/- share						
	Basic	74.91	67.13	42.75	213.68	125.74	131.57
	Diluted	74.76	66.98	42.65	213.23	125.43	131.21

All amounts in Indian Rupees millions

Sl. No.	Particulars	Standalone					
		Quarter ended	Quarter ended	Quarter ended	Nine Months ended	Nine Months ended	Year ended
		31.12.2022 (Unaudited)	30.09.2022 (Unaudited)	31.12.2021 (Unaudited)	31.12.2022 (Unaudited)	31.12.2021 (Unaudited)	31.03.2022 (Audited)
1	Total Revenue from operations	38,976	48,803	34,796	124,085	107,365	144,052
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	4,849	16,929	4,639	29,294	16,571	22,238
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	4,849	16,929	4,639	29,294	16,571	22,238
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	3,246	11,163	3,411	19,404	12,035	16,232
5	Total Comprehensive Income for the period	3,962	11,757	3,543	17,795	11,958	16,745
6	Equity Share Capital	833	832	832	833	832	832
7	Reserves (excluding Revaluation Reserve)						182,530
8	Earnings per share (in Rupees) per Rs. 5/- share						
	Basic	19.54	67.25	20.55	116.88	72.56	97.85
	Diluted	19.50	67.10	20.51	116.63	72.38	97.58

Notes:

1 The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchanges website: www.bseindia.com and www.nseindia.com and also on the Company's website: www.drreddys.com.
2 The unaudited results were reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 25 January 2023.

By order of the Board
For Dr. Reddy's Laboratories Limited

Place : Hyderabad
Date : 25 January 2023

G V Prasad
Co-Chairman & Managing Director

Dr. REDDY'S LABORATORIES LIMITED

Regd. Office: 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034, Telangana, India
CIN: L85195TG1984PLC004507, Tel: 91 40 4900 2900, Fax: 91 40 4900 2999
email: shares@drreddys.com, website: www.drreddys.com

UNITED SPIRITS LI

Regd. Office: 'UB Tower', # 24, Vittal Mallya Roa
Tel: +91 80 4544 8000, 2221 0705; Fax: +
Email: contactus.India@diageo.com Webs
Corporate Identity Number: L01551KA1

Extract of standalone and consolidated unaudited financial results for the

మూడేళ్ల చిన్నారిపై అఘాయిత్యం

• కామాంధుడికి గ్రామస్తుల దేహ శుద్ధి

గార్ల, ప్రభస్వాస్: అభం శుభం తెలియని ఓ చిన్నారిపై కామంతో కళ్లు మూసుకుపోయిన ఓ కామాంధుడు అత్యాచారానికి పాల్పడిన ఘటన బుధవారం మండల పరిధిలోని కొత్త కొత్త తండా గ్రామంలో చోటు చేసుకుంది. అదే గ్రామానికి చెందిన ఆశోక్ అనే 25 ఏళ్ల యువకుడు ఇంట్లో ఎవరూ లేని సమయంలో ఉయ్యాలలో ఉన్న చిన్నారిపై అఘాయిత్యానికి పాల్పడ్డాడు. చిన్నారి కేకలు వేయడంతో చుట్టుపక్కన ఉన్నవారు గమనించి ఆ కామాంధుడిని పట్టుకొని స్తంభానికి కట్టిన దేహ శుద్ధి చేశారు. అనంతరం ఆ కామాంధుడిని పోలీసులకు అప్పగించారు. ఘటన స్థలానికి డీఎస్పీ సదయ్య, గార్ల బయ్యారం సీబి బాలాజీ, ఎస్ఐ బానోత్ వెంకన్న చేరుకొని పోక్సో చట్టం కింద కేసు నమోదు చేసి దర్యాప్తు చేస్తున్నామని తెలిపారు.



వేసుకొని బుధవారం తెల్లవారుజామున మృతి చెందినట్లు భావిస్తున్నట్లు సీబి తెలిపారు. కాగా వృద్ధ దంపతుల మృతిపై పలు అనుమానాలు కలుగుతున్నాయి. మృతిచెందిన ఈ వృద్ధ దంపతులకు ఇద్దరు కుమారులు, కుమార్తె సంతానంకాగా, తమకున్న వ్యవసాయ భూమి గురించి తగాదా ఉన్నట్లు గ్రామస్తులు చర్చించుకుంటున్నారు. వృద్ధ దంపతుల అనుమానాస్పద మృతిపై పోలీసులు విచారణ చేపట్టారు. మృతదేహాలను పోస్టుమార్టం నిమిత్తం ఆస్పత్రికి తరలించి కేసు దర్యాప్తు చేస్తున్నట్లు భూపాలపల్లి సీబి రాజిరెడ్డి తెలిపారు.

Andhra Prabha on January 26, 2023



Extract of unaudited financial results of Dr. Reddy's Laboratories Limited and its subsidiaries for the quarter and nine months ended 31 December 2022 prepared in compliance with Indian Accounting Standards

All amounts in Indian Rupees millions

Sl. No.	Particulars	Consolidated					
		Quarter ended 31.12.2022 (Unaudited)	Quarter ended 30.09.2022 (Unaudited)	Quarter ended 31.12.2021 (Unaudited)	Nine Months ended 31.12.2022 (Unaudited)	Nine Months ended 31.12.2021 (Unaudited)	Year ended 31.03.2022 (Audited)
1	Total Revenue from operations	67,898	63,318	53,383	183,545	160,703	215,452
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	16,377	16,136	9,742	47,193	28,025	30,614
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	16,377	16,136	9,742	47,193	28,025	30,614
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	12,439	11,142	7,093	35,471	20,855	21,825
5	Total Comprehensive Income for the period	14,143	10,521	5,855	34,425	18,457	18,927
6	Equity Share Capital	833	832	832	833	832	832
7	Reserves (excluding Revaluation Reserve)						191,292
8	Earnings per share (in Rupees) per Rs. 5/- share						
	Basic	74.91	67.13	42.75	213.68	125.74	131.57
	Diluted	74.76	66.98	42.65	213.23	125.43	131.21

All amounts in Indian Rupees millions

Sl. No.	Particulars	Standalone					
		Quarter ended 31.12.2022 (Unaudited)	Quarter ended 30.09.2022 (Unaudited)	Quarter ended 31.12.2021 (Unaudited)	Nine Months ended 31.12.2022 (Unaudited)	Nine Months ended 31.12.2021 (Unaudited)	Year ended 31.03.2022 (Audited)
1	Total Revenue from operations	38,976	48,803	34,796	124,085	107,365	144,052
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	4,849	16,929	4,639	29,294	16,571	22,238
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	4,849	16,929	4,639	29,294	16,571	22,238
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	3,246	11,163	3,411	19,404	12,035	16,232
5	Total Comprehensive Income for the period	3,962	11,757	3,543	17,795	11,958	16,745
6	Equity Share Capital	833	832	832	833	832	832
7	Reserves (excluding Revaluation Reserve)						182,530
8	Earnings per share (in Rupees) per Rs. 5/- share						
	Basic	19.54	67.25	20.55	116.88	72.56	97.85
	Diluted	19.50	67.10	20.51	116.63	72.38	97.58

Notes:

- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchanges website: www.bseindia.com and www.nseindia.com and also on the Company's website: www.drreddys.com.
- The unaudited results were reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 25 January 2023.

By order of the Board
For Dr. Reddy's Laboratories Limited

Place : Hyderabad
Date : 25 January 2023

G V Prasad
Co-Chairman & Managing Director

Dr. REDDY'S LABORATORIES LIMITED

Regd. Office: 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034, Telangana, India
CIN: L85195TG1984PLC004507, Tel: 91 40 4900 2900, Fax: 91 40 4900 2999
email: shares@drreddys.com, website: www.drreddys.com